HER2+ Breast Cancer

The novel bispecific antibody TQB2930 plus chemotherapy elicited responses in heavily pretreated HER2-positive breast cancer.

Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses eliminating surgery for select patients with a pCR after neoadjuvant therapy for early breast cancer.

JSKN003 demonstrated tolerability and antitumor activity in heavily pretreated HER2-positive breast cancer.

Erika P. Hamilton, MD, highlights the unmet needs regarding treatment for brain metastases in HER2-positive metastatic breast cancer.

The FDA granted breakthrough therapy designation to first-line trastuzumab deruxtecan plus pertuzumab in HER2-positive metastatic breast cancer.

Dr Kuerer discusses the potential to omit surgery in patients with HER2-positive or triple-negative breast cancer who have pCR after neoadjuvant therapy.

Heather McArthur, MD, discusses monitoring strategies for interstitial lung disease in patients with HER2-positive breast cancer treated with trastuzumab deruxtecan.

Jessica Paulus, ScD, discusses using real-world data to add an external control arm to a study of tucatinib plus liposomal doxorubicin in HER2+ breast cancer.

Paolo Tarantino, MD, details the role of ADCs in HER2-positive breast cancer, along with unmet needs that persist.

HER2DX genomic scoring predicted pCR after neoadjuvant THP in a high-risk subgroup of patients with HER2-positive early breast cancer.

Experts in the fields of lung, head and neck, HER2+ breast, and hematologic cancers discuss notable updates for fellows from the 2025 AACR Annual Meeting.

Gedatolisib generated clinical activity in metastatic castration-resistant prostate cancer and HER2-positive breast cancer.

Treatment with KN026 plus KN046 demonstrated durable responses and a manageable safety profile in previously treated HER2-positive breast cancer.

IBI354 continued to demonstrate tolerability and was active in pretreated, HER2-positive advanced breast cancer.

Jason A. Mouabbi, MD, discusses the importance of achieving consensus for integrating CompassHER2-pCR data into early-stage HER2+ breast cancer management.

The bispecific antibody-drug conjugate TQB2102 was safe and active in pretreated, recurrent or metastatic, HER2-positive breast cancer.

As the HER2-positive breast cancer landscape continues to evolve, the omission of carboplatin in TCHP could drive significant change.

Henry Kuerer, MD, PhD, discusses considerations for the selective omission of surgery in HER2-positive breast cancer or triple-negative breast cancer.

T-DXd maintained efficacy in HR-positive, HER2-low or -ultralow metastatic breast cancer irrespective of mutational subtype.

The top 5 OncLive videos of the week cover insights in HER2+ breast cancer, myeloma, pancreatic cancer, prostate cancer, and sarcoma.

A post hoc analysis from the APHINITY trial showed statin use did not improve survival in early-stage HER2-positive breast cancer.

The top 5 OncLive videos of the week cover insights in ovarian cancer, prostate cancer, chronic lymphocytic leukemia, and breast cancer.

The FDA has approved options in non–small cell lung cancer, advanced anal cancer, and pheochromocytoma or paraganglioma, and more from OncLive this week.

T-DM1 plus palbociclib showed significant PFS in patients with HER2-positive metastatic breast cancer.

Zanidatamab/chemotherapy showed early antitumor activity with a manageable safety profile in patients with HER2-expressing metastatic breast cancer.